Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new class of once-daily oral
antihyperglycaemic agents that target the kidneys. As they act independently of insulin, SGLT2 inhibitors have
been found to be effective throughout the type 2 diabetes mellitus spectrum. Standard treatment for diabetes
carries the risk of hypoglycaemia with the management of obesity and hypertension adding to the challenge. SGLT2
inhibitors offer a favourable weight profile and low risk of hypoglycaemia.
Modern Medicine – January 2018